Category: biotech

.AbbVie has actually returned to the resource of its antipsychotic powerhouse Vraylar in search of another blockbuster, spending $25 thousand beforehand to form a brand

.On the same day that some Parkinson’s disease medicines are being actually brought into question, AbbVie has actually introduced that its own late-stage monotherapy candidate

.Monopar Therapeutics is recouping a medication coming from the scrap heap of AstraZeneca’s rare illness pipeline. It has actually accredited ALXN-1840, an applicant for the

.AstraZeneca has used artificial intelligence to create an one-of-a-kind biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), wishing to separate the antibody-drug conjugate (ADC) coming